Heart failure & cardiomyopathiesSecondary analysis
Improved Long-Term Survival with Tafamidis Treatment in Patients with Transthyretin Amyloid Cardiomyopathy and Severe Heart Failure Symptoms
- Secondary analysis of the ATTR-ACT randomised trial and its long-term extension
- open-label extension
- interim analysis
Authors' conclusion
We observed reduced all-cause mortality with continuous tafamidis treatment compared with delayed tafamidis treatment (placebo then tafamidis) in patients with NYHA class III symptoms at baseline over a median follow-up of ∼5 years.
Study context
- Population
- Patients with ATTR-CM and New York Heart Association (NYHA) class III symptoms at baseline
- Participants
- 55 vs 63
- Comparison
- Continuous tafamidis vs placebo then tafamidis
- Tafamidis 80 mgn = 55
- Placebon = 63reference
- Primary endpoint
- All-cause mortality
Primary result
All-cause mortality, NYHA class III · median follow-up 60 vs 56 months
Hazard ratio
0.64
95% CI 0.41–0.99
Tafamidis 80 mg vs Placebo
HR 0.64 (95% CI 0.41–0.99)
As reported in the abstract
Further findings
| Outcome | HR (CI) | |
|---|---|---|
| All-cause mortality, NYHA class I/II (subgroup) · median follow-up 61 and 60 months · tafamidis 80 mg n = 121; placebo n = 114 | 0.50 (0.35–0.73) | |
| 0.20.5125Hazard ratio (log scale) |
Original publication
Improved Long-Term Survival with Tafamidis Treatment in Patients with Transthyretin Amyloid Cardiomyopathy and Severe Heart Failure Symptoms. Eur J Heart Fail. Published 26 July 2023. doi:10.1002/ejhf.2974
Summarised from the published abstract; every number is checked against it